The widely anticipated release of negotiated additions to the National Reimbursement Drug List by China’s National Medical Insurance Administration came on Nov. 28, with Innovent’s Tyvyt the lone anti-PD-1 mAb to make the cut. In...

Emulate showed its Liver-Chip can both predict clinical safety issues not seen in animal models and identify mechanisms of toxicity, highlighting its benefits for guiding drug development. Emulate Inc. President and CSO Geraldine Hamilton told...

China’s ministry of finance revealed a list of 21 rare disease drugs and four APIs which will be eligible for a reduction in value-added tax beginning March 1. The government will reduce the VAT on...

Lobbyists for the biopharmaceutical industry are scrambling to use a must-pass spending bill as a vehicle to roll back provisions in a recently enacted law that would impose tens of billions of dollars in costs...

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...

FDA approved a 32 mg tablet of Tracleer bosentan to treat pulmonary arterial hypertension in children ages 3 and older. Johnson & Johnson (NYSE:JNJ) gained Tracleer in its June acquisition of Actelion Ltd. Actelion said...

FDA approved a 32 mg tablet of Tracleer bosentan to treat pulmonary arterial hypertension in children ages three and older. Johnson & Johnson (NYSE:JNJ) gained Tracleer in its June acquisition of Actelion Ltd. Actelion said...

AstraZeneca plc and Genentech Inc. have joined forces to test whether a liver spheroid system can improve upon the gold standard for preclinical prediction of hepatotoxicity. The goal is to raise the bar on preventing...

China's Ministry of Human Resources and Social Security (MoHRSS) has negotiated discounts for 36 high-cost, high-value drugs and added them to its national reimbursement drug list, according to Goldman Sachs analyst Richard Yeh. The drugs'...

A healthy biotech ecosystem comprises a continuum from big pharma and bellwether biotechs at the top to private newcos at the bottom, with a mixture of liquidity events -- predominantly M&A -- to reward investors....